Phase I/IB Multi-Center Study of Irreversible EGFR/HER2 Tyrosine Kinase Inhibitor Afatinib (BIBW2992)in Combination with Capecitabine for Advanced Solid Tumors and Pancretico- Biliary Cancers
S
Safi Shahda, MD
Primary Investigator
J
Jessica MacLean
Primary Investigator
Not Recruiting
18 years - 100 years
All
Phase
N/A
1 Location
Brief description of study
The purpose of this study is to test the safety and antitumor activity of the combination of two drugs, Afatinib and capecitabine, and to see what effects (good and bad) these drugs have on you and your cancer.
Detailed description of study
The purpose of this study is to test the safety and antitumor activity of the combination of two drugs, Afatinib and capecitabine, and to see whate effects these drugs have on Advanced Solid Tumors and Pancreatico-Biliary Cancers.
Eligibility of study
You may be eligible for this study if you meet the following criteria:
- Conditions: Advanced Solid Tumor, Pancretico- Biliary Cancer
-
Age: 18 years - 100 years
-
Gender: All
Updated on
01 Aug 2024.
Study ID: 1602693687 (CC9078)
